The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Open accessAbstract
OPINION STATEMENT: Migraine is a very disabling disorder with severe impact on patients' lives and substantive costs to society in terms of healthcare costs and lost productivity. Prevention is a key component of migraine therapy, and while numerous preventive options exist, each is burdened by either troublesome side effects or insufficient efficacy. All migraine preventives currently in clinical use were licensed for other purposes and, by chance, have efficacy against migraine. As our understanding of migraine has evolved, calcitonin gene-related peptide (CGRP) has moved to the forefront as a neuropeptide central to migraine pathophysiology. Six small molecule CGRP receptor antagonists were shown to be effective for acute treatment of migraine; two were stopped for hepatotoxicity or one for formulation concern issues and one is now in phase III. Monoclonal antibodies against CGRP or the CGRP receptor have a longer duration of action and have been investigated for migraine prevention. Four are in development and three have completed phase II and one phase III trials; every reported study has been positive. Furthermore, no safety issues have arisen to date, including hepatic or cardiovascular effects, and initial tolerability appears to be excellent. Monoclonal antibodies antagonizing the CGRP pathway represent a novel approach to prevention: a mechanism-specific migraine-targeted therapy. While we must await the results of all the phase III trials, cautious excitement seems warranted as we enter a new era of better tolerated, well-understood, bespoke migraine treatment for this common and disabling neurological disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
Rosenfeld, M. G., Mermod, J.-J., Amara, S. G., Swanson, L. W., Sawchenko, P. E., Rivier, J., Vale, W. W., & Evans, R. M. (1983) · Nature · doi:10.1038/304129a0 · Cited by 2,302
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Self-citationInterictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
Cernuda-Morollón, E., Larrosa, D., Ramón, C., Vega, J., Martínez-Camblor, P., & Pascual, J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cb72 · Cited by 468
Cited by
Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32534-0 · Cited by 457
Self-citationBlocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection
Pinho-Ribeiro, F. A., Baddal, B., Haarsma, R., O’Seaghdha, M., Yang, N. J., Blake, K. J., Portley, M., Verri, W. A., Dale, J. B., Wessels, M. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.006 · Cited by 435
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14075 · Cited by 370
Metadata
- Authors
- Tso, A. R., & Goadsby, P. J.
- Venue
- Current Treatment Options in Neurology
- Published
- 2017-06-27
- Volume
- 19
- Issue
- 8
- Pages
- 27-27
- ISSN
- 1092-8480 (ISSN-L)
- 1534-3138
- OpenAlex
- W2737197277
- Cited by
- 161
- References
- 6
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? https://app.cochat.ai/papers/10.1007/s11940-017-0463-4
- The paper
- Tso, A. R., & Goadsby, P. J. (2017). Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Current Treatment Options in Neurology. https://doi.org/10.1007/s11940-017-0463-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.